n-of-many: A new study details a strategy to scale up genetic therapies that have, to date, only been tested in n-of-1 trials. Antisense oligonucleotides were custom-made for two people with SCN2A-complex neurodevelopmental disorder, a severe childhood-onset condition that can result in autism and epileptic encephalopathy. Gene-specific haplotyping enabled researchers to identify additional people with compatible diplotypes. The investigators envision prequalifying a small set of antisense oligonucleotides that target the most common SCN2A causal variants. The Transmitter has previously covered the promise and concerns over n-of-1 trials.
Autism research spotted this week:
- “Distinct subgroups emerge in autistic males and females: Insights into sex differences from a large-scale nationwide cohort” Journal of Autism and Developmental Disorders
- “17q11.2 duplication (includes NF1 gene): A scoping review” Genetics in Medicine
- “Bioinformatic investigation of convergent proteins and cellular functions downstream of autism-associated genes” Molecular Psychiatry
- “Transcriptomic convergence and the female protective effect in autism” Nature
- “Mouse spatial transcriptomics implicates the thalamus and cortex in autism and schizophrenia” Research Square
See also: “Among brain changes studied in autism, spotlight shifts to subcortex”
